source
- Antheia secures $80 million conditional loan from DOD to expand U.S. generic drug manufacturingAntheia, a biosynthesis manufacturer, has been awarded a conditional loan of $80 million from the U.S. Department of Defense. The funding is aimed at onshoring the company’s generic drug productio…
- EyePoint cuts half its staff and ends wet AMD trials after second Phase 3 failure, pivots to diabetic macular edemaEyePoint said it is launching a strategic review after its investigational drug duravyu failed another Phase 3 study in wet age‑related macular degeneration. The company reported that the top‑line…